<?xml version="1.0" encoding="UTF-8"?>
<p id="p0050">According to currently available data, at the time of submission of this article, approximately 80% of individuals who become infected with SARS-CoV-2 will experience a relatively mild, short duration syndrome; with many being wholly asymptomatic. The other 20% of SARS-CoV-2 infected patients will progress to exhibit a severe variant of this infection characterized by fever and a respiratory tract ‘flu-like’ illness. They may suffer from fever, cough, pharyngitis, headache, dyspnea, myalgias, chest pain, nausea, vomiting, confusion, and interestingly, anosmia and dysgeusia in a small albeit conspicuous proportion of patients (~5%) [
 <xref rid="bb0045" ref-type="bibr">[9]</xref>, 
 <xref rid="bb0050" ref-type="bibr">[10]</xref>, 
 <xref rid="bb0055" ref-type="bibr">[11]</xref>]. This severe disease transitions to an accelerated course of predominant respiratory deterioration, requiring intensive multidisciplinary management, including respiratory support with pressure ventilation. Addtionally, there is a high predilection for a diverse constellation multi-organ derangements, with the most severely affected individuals exhibiting multi-organ failure [
 <xref rid="bb0010" ref-type="bibr">2</xref>].
</p>
